Sareum Hldgs Plc (LON:SAR)
21.00p-8.70%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Phase 1 data validated, but accelerating cash burn threatens runway before any licensing partner emerges.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical tria…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £30.9M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Sareum Hldgs Plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free